This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
by Kinjel Shah
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.
Is Most-Watched Stock CRISPR Therapeutics AG (CRSP) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reachead $59.60 at the closing of the latest trading day, reflecting a -1.6% change compared to its last close.
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
by Zacks Equity Research
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $65.26, representing a +0.66% change from its previous close.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
by Zacks Equity Research
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
by Zacks Equity Research
Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $55.89, indicating a +1.49% shift from the previous trading day.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.91, moving +0.34% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.02, representing a -0.05% change from its previous close.
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.